Renalytix to Present at the 41st Annual Canaccord Genuity Global Growth Conference
Renalytix (NASDAQ: RNLX) will present at the 41st Annual Canaccord Genuity Virtual Global Growth Conference on August 11, 2021, at 2:30 PM EDT.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Renalytix (NASDAQ: RNLX) will present at the 41st Annual Canaccord Genuity Virtual Global Growth Conference on August 11, 2021, at 2:30 PM EDT. The presentation will be accessible via a live and archived webcast on the company's website in the investors section.
Renalytix focuses on developing AI-enabled clinical diagnostics for kidney disease, aiming to enhance diagnosis, clinical care, and drug discovery related to one of the most prevalent chronic health issues.
Details
News Market Reaction – RNLX
The recorded move for RNLX in the trading session of this news was +1.56%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, July 26, 2021 (GLOBE NEWSWIRE) -- Renalytix plc (LSE: RENX) (NASDAQ: RNLX) (“Renalytix” or the “Company”) today announced the company will be presenting at the upcoming 41st Annual Canaccord Genuity Virtual Global Growth Conference.
Renalytix’s management is scheduled to present at the Canaccord Genuity Global Growth Conference on Wednesday, August 11 at 2:30pm EDT. Interested parties may access a live and archived webcast of the presentations on the “Investors” section of the company website at investors.renalytix.com.
For further information, please contact:
UK Investor Contact:
| Walbrook PR Limited | Tel: 020 7933 8780 or renalytix@walbrookpr.com | |
| Paul McManus / Lianne Cawthorne | Mob: 07980 541 893 / 07584 391 303 | |
US Investor Contact:
| Gilmartin Group | investors@renalytix.com | |
| Carrie Mendivil / Mary Kate McDonough | 415-937-5405 | |
About Renalytix
Renalytix is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. Renalytix's products are being designed to make significant improvements in kidney disease diagnosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery. For more information, visit www.renalytix.com.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.